Article
Combination of RUNX1 inhibitor and gemcitabine to mitigate chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2a-axis-mediated endoplasmic reticulum stress
2023-05-23
Abstract excerpt
<title>Abstract</title><p><bold>Background:</bold>Gemcitabine (GEM)-based chemotherapy is the standard treatment for pancreatic ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its efficacy, and the specific mechanisms remain largely unknown. RUNX1, a key transcription factor in hematopoiesis, also involved in the malignant progression of PDAC, but was unclear in the chemoresistance...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 88e1e16a-3a36-59cf-a597-68fe871b904a
- DOI
- 10.21203/rs.3.rs-2944766/v1
